178 related articles for article (PubMed ID: 38508753)
1. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II
Carvajal-Moreno J; Wang X; Hernandez VA; Mondal M; Zhao X; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2024 Apr; 389(2):186-196. PubMed ID: 38508753
[TBL] [Abstract][Full Text] [Related]
2. Effects of hsa-miR-9-3p and hsa-miR-9-5p on Topoisomerase II
Carvajal-Moreno J; Hernandez VA; Wang X; Li J; Yalowich JC; Elton TS
J Pharmacol Exp Ther; 2023 Feb; 384(2):265-276. PubMed ID: 36410793
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9 Genome Editing of the Human Topoisomerase II
Hernandez VA; Carvajal-Moreno J; Papa JL; Shkolnikov N; Li J; Ozer HG; Yalowich JC; Elton TS
Mol Pharmacol; 2021 Mar; 99(3):226-241. PubMed ID: 33446509
[TBL] [Abstract][Full Text] [Related]
4. Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
Hernandez VA; Carvajal-Moreno J; Wang X; Pietrzak M; Yalowich JC; Elton TS
PLoS One; 2022; 17(5):e0265794. PubMed ID: 35617303
[TBL] [Abstract][Full Text] [Related]
5. hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II
Kania EE; Carvajal-Moreno J; Hernandez VA; English A; Papa JL; Shkolnikov N; Ozer HG; Yilmaz AS; Yalowich JC; Elton TS
Mol Pharmacol; 2020 Mar; 97(3):159-170. PubMed ID: 31836624
[TBL] [Abstract][Full Text] [Related]
6. Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
Kanagasabai R; Serdar L; Karmahapatra S; Kientz CA; Ellis J; Ritke MK; Elton TS; Yalowich JC
J Pharmacol Exp Ther; 2017 Jan; 360(1):152-163. PubMed ID: 27974648
[TBL] [Abstract][Full Text] [Related]
7.
Wang X; Carvajal-Moreno J; Zhao X; Li J; Hernandez VA; Yalowich JC; Elton TS
Mol Pharmacol; 2024 May; ():. PubMed ID: 38719474
[TBL] [Abstract][Full Text] [Related]
8. The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase II
Kanagasabai R; Karmahapatra S; Kientz CA; Yu Y; Hernandez VA; Kania EE; Yalowich JC; Elton TS
Mol Pharmacol; 2018 May; 93(5):515-525. PubMed ID: 29514855
[TBL] [Abstract][Full Text] [Related]
9. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
10. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
11. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
12. Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.
Ritke MK; Roberts D; Allan WP; Raymond J; Bergoltz VV; Yalowich JC
Br J Cancer; 1994 Apr; 69(4):687-97. PubMed ID: 8142256
[TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
[TBL] [Abstract][Full Text] [Related]
14. Intronic Polyadenylation in Acquired Cancer Drug Resistance Circumvented by Utilizing CRISPR/Cas9 with Homology-Directed Repair: The Tale of Human DNA Topoisomerase IIα.
Elton TS; Hernandez VA; Carvajal-Moreno J; Wang X; Ipinmoroti D; Yalowich JC
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804920
[TBL] [Abstract][Full Text] [Related]
15. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
[TBL] [Abstract][Full Text] [Related]
16. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide.
Ritke MK; Yalowich JC
Biochem Pharmacol; 1993 Dec; 46(11):2007-20. PubMed ID: 8267650
[TBL] [Abstract][Full Text] [Related]
17. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
18. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
Ma Y; North BJ; Shu J
Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
[TBL] [Abstract][Full Text] [Related]
19. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
20. Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.
Azarova AM; Lyu YL; Lin CP; Tsai YC; Lau JY; Wang JC; Liu LF
Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11014-9. PubMed ID: 17578914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]